United Therapeutics Corporation

NASDAQ:UTHR

Biotechnology

Healthcare
$577.34 -3.27%

-$18.01 today

Market cap
$24.59B
Beta
0.57
P/E (TTM)
18.0
EPS (TTM)
$29.60
52W Low $272.12High $609.35

Volume 0.42M

Average 0.52M

UTHR Accounts Payables

Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.

United Therapeutics CorporationNASDAQ: UTHR

Accounts Payables · Q2 FY2026 · quarter ended Jun 2026

Accounts payables turns negative

Q2 FY2026 accounts payables was -$4M, compared with $0 a year earlier. Trailing-twelve-month accounts payables was $81.2M.

Context

  • Accounts payables amounted to 3.1% of revenue in FY2025, up 3.1 pp from a year earlier.
  • Accounts payables increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly accounts payables holds near -$4M or moves back toward the trailing-twelve-month quarterly average of $20.3M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$4M-68.5% QoQ
Last fiscal yearDec 2025
$97.9M— YoY
LTMJun 2026
$81.2M— YoY
Accounts Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Payables history

USD · from the cash flow

Latest · FY2025
97.9M USD
Year-over-year change
—

Accounts Payables vs competitors

How UTHR compares with its peers on the latest reported figures

  • UTHR's LTM Jun 2026 accounts payables of $81.2M is the 2nd largest of the 5 companies compared; the peer median is $1.31M.
  • Accounts payables amounts to 2.6% of revenue for UTHR, versus a peer median of 2.6%.
UTHR Competitors Peer median
Accounts Payables for UTHR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
INSMInsmed IncorporatedLTM Jun 2026$170.85M +2736.6%+26.0%15.0%
UTHRUnited Therapeutics CorporationLTM Jun 2026$81.2M ——2.6%
LQDALiquidia CorporationLTM Jun 2026$11.7M -361.8%—2.6%
TVTXTravere Therapeutics, Inc.LTM Sep 2026$2.72M +151.1%—0.4%
IKTInhibikase Therapeutics, Inc.LTM Mar 2026$104.75K -122.1%+33.7%—
Peer median (excluding UTHR) $1.31M+14.5%+29.9%2.6%

Competitors are the stored peer set for UTHR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income475.8M727.3M984.8M1.2B1.33B
Depreciation & Amortization49.9M51.3M53.2M72.5M85.6M
Deferred Income Tax000097.7M
Stock-Based Compensation138.5M106.8M39.1M144M147.7M
Change in Working Capital(174.2M)(141.2M)(97.8M)(60.2M)(106.4M)
Accounts Receivables(41.3M)(21.7M)(58.5M)(400K)(70.9M)
Inventory(7.5M)(13.4M)(13.6M)(46.9M)(52.6M)
Accounts Payables000097.9M
Other Working Capital(125.4M)(106.1M)(25.7M)(12.9M)(80.9M)
Other Non-Cash Items108.2M58.3M(1.3M)(24.3M)2M
Operating Cash Flow598.2M802.5M978M1.33B1.56B
Capital Expenditures(120.8M)(138.8M)(230.4M)(246.5M)(520.5M)
Acquisitions (Net)0(1.5M)(89.2M)(30.5M)0
Purchases of Investments(1.9B)(1.71B)(2.51B)(1.65B)(3.46B)
Sales of Investments1.53B1.03B2.14B2.37B1.58B
Other Investing Activities03.5M(23M)(28.5M)1.85B
Investing Cash Flow(486.9M)(811.5M)(719.6M)417.2M(551.3M)
Debt Repayment00(100M)(400M)(300M)
Common Stock Issued0000183.1M
Common Stock Repurchased(10.8M)(11.4M)(13.8M)(1.01B)(1B)
Dividends Paid00000
Other Financing Activities55.6M86.8M101.9M157.4M(33.1M)
Financing Cash Flow44.8M75.4M(11.9M)(1.25B)(1.15B)
Effect of Forex Changes00000
Net Change in Cash156.1M66.4M246.5M489.5M(140.1M)
Free Cash Flow477.4M663.7M747.6M1.08B1.04B

United Therapeutics Corporation

NASDAQ:UTHR

Intrinsic Alpha fair value

Locked

Current Price

$577.34

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.